Similar articles

• Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.

  Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Pond GR, et al. Eur Urol. 2012 Feb;61(2):363-9. doi: 10.1016/j.eururo.2011.06.034. Epub 2011 Jun 22. Eur Urol. 2012. PMID: 21715086 Free PMC article.
• Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

  Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Tannock IF, et al. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4. Lancet Oncol. 2013. PMID: 23742877 Clinical Trial.
• Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.

  Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Pond GR, et al. Clin Genitourin Cancer. 2012 Dec;10(4):239-45. doi: 10.1016/j.clgc.2012.06.004. Epub 2012 Sep 19. Clin Genitourin Cancer. 2012. PMID: 23000202 Clinical Trial.
• Future directions in the treatment of androgen-independent prostate cancer.

  Petrylak DP. Petrylak DP. Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020. Urology. 2005. PMID: 15939077 Review.
• The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.

  Diamond E, Garcias Mdel C, Karir B, Tagawa ST. Diamond E, et al. Curr Treat Options Oncol. 2015 Feb;16(2):9. doi: 10.1007/s11864-014-0324-2. Curr Treat Options Oncol. 2015. PMID: 25762124 Review.